Senti Biosciences Holdings (SNTI) Non Operating Income (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Non Operating Income of $97000.0 for Q4 2025, down 99.38% year-over-year from $15.6 million in Q4 2024, and up 108.23% quarter-over-quarter from -$1.2 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Non Operating Income (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Non Operating Income history runs 5 years deep, the most recent figure standing at $97000.0 for Q4 2025.
- In Q4 2025, Non Operating Income fell 99.38% year-over-year to $97000.0; the TTM figure through Dec 2025 stood at $1.5 million (down 82.13% YoY), while the FY2025 annual figure was $927000.0, down 88.76% from the prior year.
- Non Operating Income for Q4 2025 stood at $97000.0, up from -$1.2 million in the prior quarter.
- The five-year high for Non Operating Income was $15.6 million in Q4 2024, with the low at -$14.9 million in Q4 2021.
- The 5-year median for Non Operating Income is $445000.0 (2022), against an average of $1.3 million.
- Peak annual rise in Non Operating Income reached 3551.88% in 2024, while the deepest fall reached 288.0% in 2024.
- Senti Biosciences Holdings' Non Operating Income stood at -$14.9 million in 2021, then jumped by 179.61% to $11.8 million in 2022, then plunged by 96.4% to $426000.0 in 2023, then soared by 3551.88% to $15.6 million in 2024, then tumbled by 99.38% to $97000.0 in 2025.
- Business Quant data shows SNTI's Non Operating Income at $97000.0 in Q4 2025, -$1.2 million in Q3 2025, and $270000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | 1.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 97,000.00 |
| Sep 30, 2025 | -1.18 Mn |
| Jun 30, 2025 | 270,000.00 |
| Mar 31, 2025 | 2.29 Mn |
| Dec 31, 2024 | 15.56 Mn |
| Sep 30, 2024 | -13.65 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Mar 31, 2024 | 4.19 Mn |
| Dec 31, 2023 | 426,000.00 |
| Sep 30, 2023 | 7.26 Mn |
| Jun 30, 2023 | 938,000.00 |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 11.85 Mn |
| Sep 30, 2022 | 445,000.00 |
| Jun 30, 2022 | 10.22 Mn |
| Mar 31, 2022 | -50,000.00 |
| Dec 31, 2021 | -14.88 Mn |
| Sep 30, 2021 | 17,000.00 |
| Jun 30, 2021 | -3.01 Mn |